Yuri Errante

Yuri Errante

Auto-generated profile, based on publicly available information

Yuri Errante

University Campus Bio-Medico di Roma

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Investigative Radiology
Verified
Journal Article
Closed access
YEYuri Errante
Yuri Errante
VCVincenzo Cirimele
Vincenzo Cirimele
Carlo Augusto MallioCarlo Augusto Mallio
Carlo Augusto Mallio
VLVincenzo Di Lazzaro
Vincenzo Di Lazzaro
Bruno Beomonte ZobelBruno Beomonte Zobel
Bruno Beomonte Zobel
CQCarlo Cosimo Quattrocchi
Carlo Cosimo Quattrocchi
The purpose of this study was to assess the association between the serial number of gadolinium-enhanced magnetic resonance imaging (MRI) examinations and the signal hyperintensity of the dentate nucleus on unenhanced T1-weighted images in patients with multiple sclerosis (MS) and those with brain metastases (BMs). A group of 38 patients with MS and 37 patients with BM who had undergone at least 2 consecutive enhanced MRI examinations in our institution were examined for this retrospective observational study. The average T1 signal intensity of the dentate nuclei and the pons was obtained, and the dentate nuclei-to-pons (DNP) signal intensity ratio was calculated. These values were compared between patients with less than 6 and 6 enhanced MRI scans or more (eMRI). Relative changes of the DNP were plotted against the number of enhanced MRI scans (eMRIn). A progressive increase in the T1 signal intensity of the DNP ratio was observed both in the MS group and in the BM group. The DNP ratios of the last eMRI scans in the subgroup of patients with 6 eMRI scans or more were significantly higher than those of the first eMRI scan in the MS group (P < 0.001) and in the BM group (P < 0.01). Relative changes of the DNP showed a positive correlation with the eMRIn with a Spearman ρ of 0.96 (P < 0.001) in the MS group and that of 0.88 (P < 0.001) in the BM group. Curve regression analyses of the relative change of DNP ratios showed linear models to best fit the data with r(2) of 0.89 in the MS group and r(2) of 0.74 in the BM group. Our study shows that the increase in the unenhanced T1 signal intensity has a linear relationship with the eMRIn in patients with MS and BM. Indeed, we estimated a linear regression model to fit the progressive increase in T1 signal intensity of the dentate nucleus after multiple enhanced MRI scans. This finding suggests substantial dechelation of gadodiamide in patients with normal renal function, raising further concerns regarding the stability of this agent. Further comparative studies with other gadolinium chelates, specifically both linear and macrocyclic, are strongly recommended.

1 July 2015 in Investigative Radiology
Verified
Journal Article
Closed access
CQCarlo Cosimo Quattrocchi
Carlo Cosimo Quattrocchi
Carlo Augusto MallioCarlo Augusto Mallio
Carlo Augusto Mallio
YEYuri Errante
Yuri Errante
VCVincenzo Cirimele
Vincenzo Cirimele
LCLuciano Carideo
Luciano Carideo
Bruno Beomonte ZobelBruno Beomonte Zobel
Bruno Beomonte Zobel
The dentate nucleus of the cerebellum may appear as hyperintense on unenhanced T1 magnetic resonance images (MRIs) of the brain. Recently, T1 signal hyperintensity has received attention owing to data on the association of this finding with the history of multiple injections of gadolinium-based contrast agents, specifically gadodiamide, in patients with multiple sclerosis and brain metastases. We conducted a retrospective study on patients with a meningioma who had routinely undergone follow-up enhanced MRI scans with gadodiamide. Across a time interval of 18 months (from January 2013 to July 2014), we identified 102 consecutive patients eligible for this study. A significant increase in T1 hyperintensity of the dentate nuclei of the cerebellum on nonenhanced scans was observed between the first and the last MRI in the group of patients with a history of at least 6 enhanced MRI scans (P < 0.01), whereas no differences were observed in the group with 1 to 5 enhanced MRI scans (P = 0.74). Further research is necessary to shed light on the mechanism of the T1 hyperintensity as well as on the histological and microstructural appearance of the dentate nucleus after multiple intravenous injections of gadodiamide. The finding raises the question of substantial dechelation of this agent in patients with normal renal function.

18 July 2012 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
CQCarlo Cosimo Quattrocchi
Carlo Cosimo Quattrocchi
YEYuri Errante
Yuri Errante
CGChiara Gaudino
Chiara Gaudino
Carlo Augusto MallioCarlo Augusto Mallio
Carlo Augusto Mallio
AGAlessandro Giona
Alessandro Giona
Bruno Beomonte ZobelBruno Beomonte Zobel
Bruno Beomonte Zobel

1 January 2016 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
CAClaudia Altamura
Claudia Altamura
FSFederica Scrascia
Federica Scrascia
CQCarlo Cosimo Quattrocchi
Carlo Cosimo Quattrocchi
YEYuri Errante
Yuri Errante
EGEmma Gangemi
Emma Gangemi
FVFabrizio Vernieri
Fabrizio Vernieri
Altamura C, et al. J Clin Neurol. 2016 Apr;12(2):201-208. http://dx.doi.org/10.3988/jcn.2016.12.2.201

30 May 2015 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
CAClaudia Altamura
Claudia Altamura
MVMariacarla Ventriglia
Mariacarla Ventriglia
MMMaria Giulia Martini
Maria Giulia Martini
Domenico MontesanoDomenico Montesano
Domenico Montesano
YEYuri Errante
Yuri Errante
Vincenzo Di MarzoVincenzo Di Marzo
Vincenzo Di Marzo
Growing evidence suggests that the endocannabinoid system is involved in the pathogenesis of Alzheimer's disease (AD) and atherosclerosis. The purpose of this study was to investigate the activation of the endocannabinoid system in AD in vivo and the possible intermediate role of atherosclerosis. We enrolled 41 patients with probable AD, and 30 age- and gender-matched controls. All subjects underwent: ultrasound examination of cerebral and neck vessels (including intima-media thickness and plaque stenosis evaluation); blood sampling to measure levels of endocannabinoid [anandamide (AEA), 2-arachidonoylglycerol (2-AG)] and endogenous AEA analogues [N-palmitoyl-ethanolamide (PEA); N-oleoyl-ethanolamide]; neuropsychological evaluation and brain MRI (atrophy, white matter hyperintensity volume). 2-AG levels were higher in AD patients compared to controls (Mann-Whitney test p = 0.021). In the AD group, 2-AG correlated to white matter hyperintensity volume (r = 0.415, p = 0.015) and was higher in patients with chronic heart ischemic disease (p = 0.023). In AD patients, 2-AG was also positively related to memory (r = 0.334, p = 0.05) and attention (r = 0.423, p = 0.018) performances. Constructional praxia test scores were lower in patients with higher levels of PEA (r =-0.389, p = 0.019). AD patients present high plasma 2-AG levels, also in relation to heart ischemic disease and cerebral leukoaraiosis. This may be a protective mechanism hindering neurodegeneration, but it may also play an ambivalent role on cerebrovascular circulation. The increase in 2-AG and PEA levels observed with ongoing pathological processes may differently modulate cognitive performances.

1 May 2013 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
PMPaola Maggio
Paola Maggio
CAClaudia Altamura
Claudia Altamura
DLDoriana Landi
Doriana Landi
SMSimone Migliore
Simone Migliore
DLDomenico Lupoi
Domenico Lupoi
FVFabrizio Vernieri
Fabrizio Vernieri